Clinical Trial Search

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin — 15894.7; 19505.7; 25415.5…

Primary: Change in Glucose Tolerance as Measured by Area-under-the-curve — 328; 1000 AUC - mg*min/dL — p=0.5582

Primary: Hepatic Fatty Acid Oxidation — 0.052; 0.045; 0.042 micromol/ml/min

Primary: Change in the Liver Triglycerides (TG). — 13.2; 6.4; 12.3; 10.6 percentage of liver triglycerides

Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146

Primary: Baseline Glucose Utilization — 0.0062; 0.0035 µmol/kgFFM/pmol insulin/min

Primary: Change in Total Mass and Regional Adipose Adiposiy — 0.3; -1.4; -0.9; -0.7 kilograms — p=0.77

Primary: Change From Baseline in Glucose Disposal Rate: Insulin Ratio During Steady State (M/I) — 0.055; 0.004 mg/kg/min per microU/ml

Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67

Primary: Absolute Relative Difference (ARD) — 19.1; 14.9; 21.8; 20.4 percentage of error

Primary: The Change in Plasma Glucagon Levels (Pmol/L) Measured During Normoglycaemic and Hypoglycaemia — 1.34; 1.68; 2.26; 0.31 pmol/L — p=>0.99

Primary: Rate of Exogenous Glucose Oxidation — 0.31; 0.32 g/min

Primary: Average Myocardial Blood Flow — 0.73; 0.97 mL/g/minute — p=<0.005

Primary: Hepatic Fat Fraction — 8; 7.3 percent hepatic fat

Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…